Access all of the content
It was lovely to speak with Dr Beatriz Mateos (Universidad de Alcalá, Madrid, Spain) about the findings from her research into the impact of tenofovir on the severity of COVID-19 infection in those with chronic hepatitis B.
Her presentation entitled ‘Tenofovir reduces the severity of COVID-19 infection in chronic hepatitis B patients’ was given at EASL ILC 2021, 23-26 June.
- What was the rationale for investigating antiviral treatments, such as tenofovir and entecavir, in the treatment of COVID-19 infection for those with chronic hepatitis B? (0:23)
- Could you briefly summarise the aims of your study, the methods used and the analysis performed? (1:00)
- What were the key clinical findings from the research? (2:23)
- Based on these findings, could tenofovir be providing a protective effect from severe COVID-19 symptoms and what could the clinical impact of these findings be? (3:09)
Disclosures: Dr Beatriz Mateos has nothing to disclose in relation to this video interview
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
Share this Video
Related Videos In Viral Infections
DANFLU-1: post-hoc analysis of high-dose quadrivalent influenza vaccines: Niklas Dyrby Johansen, ECCMID 2023
DANFLU-1 was an open-label, active-controlled, individually randomized trial conducted in Denmark during the 2021/2022 northern hemisphere influenza season. Dr Niklas Dyrby Johansen (University of Copenhagen Copenhagen, Denmark) discusses the post-hoc analysis from DANFLU-1 which investigated the effects of high-dose quadrivalent influenza vaccine (QIV-HD) vs standard-dose quadrivalent influenza vaccine (QIV-SD). The abstract ‘Relative effectiveness of high-dose […]
Michael Ison, IDWeek 2022: Respiratory syncytial virus (RSV) – Health burden and current vaccine candidates
Respiratory syncytial virus (RSV) present a significant disease burden in children and older adults. Currently, there are no approved vaccines against RSV. In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the health burden of RSV infection in older adults, and current […]
Michael Ison, IDWeek 2022: Respiratory syncytial virus (RSV) prefusion F protein candidate vaccine RSVPreF3 OA – Ongoing phase 3 study results
Respiratory syncytial virus (RSV) presents a significant disease burden in older adults, with no approved vaccines to protect against RSV. In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the findings from an ongoing phase 3 study investigating vaccine efficacy of the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!